Home › Research › Disparities
Impact of FDA black box advisory on antipsychotic medication use
Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC.. Archives of internal medicine, 2010-01-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Background In April 2005, the US Food and Drug Administration (FDA) issued an advisory and subsequent black box warning regarding the risks of atypical anti psychotic use among elderly patients with dementia. The impact of these warnings on atypical drug use is unknown. Methods We used quasi-experimental, interrupted time-series analyses to examine nationally representative data from IMS Health's National Disease and Therapeutic Index from January 2003 through December 2008. The primary measurement from this audit of office-based physicians was the use of an atypical antipsychotic agent. We quantified the impact of the advisory on atypical antipsychotic use among all individuals and those 65 years or older with dementia. Results From January 2003 to March 2005, mentions of total atypical antipsychotic drugs increased at an annual rate of 34%, and among patients with dementia, 16%. In the year prior to the FDA advisory, there were approximately 13.6 million atypical drug mentions, including 0.8 million among those with dementia. In the year following the advisory, atypical drug mentions fell 2% overall and 19% among those with dementia. In 2004, 19% (0.8 of 4.1 million) of drug mentions for dementia were for an atypical agent. By 2008, this proportion decreased to 9% (0.4 of 4.3 million). Atypical drug use slowed for both FDA-approved and off-label indications and declined through 2008 for all populations examined. Conclusion The FDA advisory was associated with decreases in the use of atypical antipsychotics, especially among elderly patients with dementia.
What this study adds
Evidence grade: Low
This study found that the FDA advisory and black box warning regarding the risks of atypical antipsychotic use among elderly patients with dementia was associated with decreases in the use of atypical antipsychotics, especially among elderly patients with dementia. It also found that atypical drug use slowed for both FDA-approved and off-label indications.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dorsey, E. R., Rabbani, A., Gallagher, S. A., Conti, R. M., & Alexander, G. C. (2010). Impact of FDA black box advisory on antipsychotic medication use. Archives of internal medicine. https://doi.org/10.1001/archinternmed.2009.456
Vancouver
Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Archives of internal medicine. 2010. doi:10.1001/archinternmed.2009.456. PMID: 20065205.
BibTeX
@article{dorsey2010-20065205,
author = {Dorsey, E. R. and Rabbani, A. and Gallagher, S. A. and Conti, R. M. and Alexander, G. C.},
title = {{Impact of FDA black box advisory on antipsychotic medication use}},
journal = {Archives of internal medicine},
year = {2010},
doi = {10.1001/archinternmed.2009.456},
pmid = {20065205},
url = {https://doi.org/10.1001/archinternmed.2009.456}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results From January 2003 to March 2005, mentions of total atypical antipsychotic drugs increased at an annual rate of 34%, and among patients with dementia, 16%.
- In the year following the advisory, atypical drug mentions fell 2% overall and 19% among those with dementia.
- Conclusion The FDA advisory was associated with decreases in the use of atypical antipsychotics, especially among elderly patients with dementia.
Why it matters
This study found that the FDA advisory and black box warning regarding the risks of atypical antipsychotic use among elderly patients with dementia was associated with decreases in the use of atypical antipsychotics, especially among elderly patients with dementia. It also found that atypical drug use slowed for both FDA-approved and off-label indications.
New to this subject? Start with our plain-English guide: Disparities →
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Archives of internal medicine) |
| Journal's citation record | 3 / 4 | Archives of Internal Medicine: journal h-index 462 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 242 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 13.4 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 3 / 6 | Cited 7.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 21 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Earl Ray Dorsey: h-index 61 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Rochester Medicine: institution h-index 953 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20065205) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/archinternmed.2009.456
- PubMed: 20065205
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Disparities from nearby years
Also in Disparities
98 studies in the library are filed under Disparities with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Disparities hub.